Major depressive disorder is a leading cause of disability worldwide. Because conventional
therapies are ineffective in many patients, novel strategies are needed to overcome …

Ketamine is an effective antidepressant, but there is substantial variability in patient
response and the precise mechanism of action is unclear. Neuroimaging can provide …

The glutamatergic modulator ketamine is associated with changes in sleep, depression, and
suicidal ideation (SI). This study sought to evaluate differences in arousal-related sleep …

The discovery of racemic (R, S)-ketamine as a rapid-acting antidepressant and the
subsequent FDA approval of its (S)-enantiomer, esketamine, for treatment-resistant …

Evidence supporting specific therapies for late-life treatment-resistant depression (LL-TRD)
is necessary. This study used Bayesian adaptive randomization to determine the optimal …

Background Whether cortical excitation and inhibition functions differ between patients with
treatment-resistant depression (TRD) and strong suicidal ideation (SI) and healthy subjects …

Neuroplasticity during sensitive periods, the molecular and cellular process of enduring
neural change in response to external stimuli during windows of high environmental …

Introduction: Repetitive transcranial magnetic stimulation (rTMS) alleviates symptoms of
major depressive disorder, but its neurobiological mechanisms remain to be fully …

Since 2018, significant advances have been made to treat major depression and
treatmentresistant major depression (TRD). These include the FDA approvals of esketamine …

Background: Repetitive transcranial magnetic stimulation (rTMS) has attracted attention for
treating treatment-resistant major depressive disorder (MDD) because of its effectiveness …